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Introduction
Human monocytes (Mo) and monocyte-derived macrophages (MdM) are considered to be major effectors in host defense mechanisms against cancer. 1, 2 Early on, the Mo/MdM were described as cells with a major role in phagocytic functions directed towards micro-organisms and cancer cells. Later, it was shown that mononuclear cells could initiate and amplify the immune response through their abilities to process and present antigens 3, 4 and to produce cytokines. [5] [6] [7] To perform their antitumoral activity, Mo/MdM must be recruited and activated. The term 'activated Mo/MdM' is rather ill-defined. Here, we use the notion of 'activation' as the process by which noncytotoxic Mo/MdM acquire the ability to lyse tumorigenic cells. Indeed, an interesting capacity of activated monocytes/macrophages is their specific antitumoral cytotoxic activity, whether antibody-dependent 8 or -independent; 9 the latter involving a direct interaction of mononuclear phagocytes with tumor cells. Even though this mechanism has not yet been completely elucidated, it is known that cytotoxicity, in an in vitro model, is directed specifically towards neoplastic cells without damage to other cells, even in coculture conditions. 10 Freshly isolated human monocytes show significant, though variable, levels of cytotoxicity in the absence of deliberate stimulation. 11 Several studies have shown that monocyte activation by various compounds such as lipo- 12 or tripeptide (MTP), 13 microbial products (LPS) 14 and lymphokines (IFN-␥), [15] [16] [17] increase the cytotoxic functions of these cells in vitro or in vivo. However, the efforts to activate the tumoricidal properties of Mo/MdM in vivo were unsuccessful due to the very short half-life of intravenously injected human recombinant IFN-␥ and severe toxic effects were observed with high doses of cytokines. Furthermore, only a small fraction of phagocytic cells is able to respond to circulating cytokines. 18 The clinical interest of rhIFN-␥ in ex vivo adoptive cellular immunotherapy protocols has been evaluated in several phase I and II trials with cancer patients. [19] [20] [21] Again in these therapeutical approaches, the major problem was the short duration of ex vivo activation by rhIFN-␥ entailing repeated injections of activated cells to obtain a clinical response. With this limitation in mind, we have developed a gene transfer protocol with IFN-␥ cDNA. Our aim was to obtain an efficient long-lasting autocrine cytocidal activation in transfected human Mo/MdM. Since Mo/MdM have long half-lives (months) they could represent ideal cellular vectors for an effective gene therapy.
In previous experiments, we assessed transfection of human monocytes using a cationic lipid, DOGS (dioctadecylamido glycylspermine, Transfectam) 22 and ␤-galactosidase (␤-gal) as a reporter gene (pCMV␤gal). Histochemical staining showed up to 30% of cells to be transfected, but cells from some patients were refractory to the transfection. 23 Transmission electron microscopy (TEM) showed intracellular complexes (synthetic vector/DNA) to be present in more than 90% of the monocytes exposed to DOGS/DNA. 24 The presence of ␤-galactosidase mRNA was detected by RT-PCR in all cell samples. Our working hypothesis was that, even if the level of ␤-gal transgene in Mo was very low and undetectable by histochemical techniques, we could still use a cytokine cDNA (IFN-␥) and expression levels obtained might still be sufficient to induce a cellular modification such as cytotoxic activation of Mo.
To test this hypothesis we transfected Mo with ExGen 500 a new cationic polymer and a member of the polyethyleneimine (PEI) family. 25, 26 Four different plasmids including the IFN-␥ cDNA were tested. Transfection was characterized by RT-PCR of the transgenic mRNA and the resulting cytotoxic activation was measured by a clonogenic coculture assay. We show that the mRNA for IFN-␥ can be detected up to 2 weeks after transfection. Moreover we obtained an in vitro cytotoxic efficacy significantly greater than that obtained with rhIFN-␥ in the same conditions. Thus, human monocytes can be efficiently transduced by a nonviral vector with IFN-␥ cDNA to provide a tumoricidal action.
Results
The rhIFN-␥ has no effect on the CMV promoter It has been previously reported that IFN-␥ can inhibit transgene expression driven by the wild-type CMV promoter. 27 In the experiment performed by Harms et al 27 the authors showed that IFN-␥ regulation was played out at the level of particular sequences: the interferon responsive elements (IRE). To study the potential effects of IFN-␥ on the CMV promoter used in our studies, we transfected the human colon carcinoma cell line, LoVo, with the ␤-galactosidase gene driven by the CMV promoter (pCMV␤gal). As a control, we used the same gene driven by the human ␤-actin promoter (p␤act/␤gal). Transfections were performed in the presence or absence of 100 U/ml of rhIFN-␥. As shown in Figure 1 , there was no significant difference between ␤-galactosidase expression levels in untreated and rhIFN-␥-treated cells whether transfected with p␤act/␤gal or pCMV␤gal.
PEI transfected monocytes express IFN-␥ mRNA up to 15 days after transfection As described in Materials and methods, after transfection we analyzed the presence of mRNA by RT-PCR with pairs of primers specific for IFN-␥ cDNA inserted into pLo1-pL20, pLo2 and pL3I33 at days 1, 7 and 14 (plasmids maps are shown in Figure 2 ). In all cases a specific band was found up to day 14 ( Figure 3 ).
Cytotoxicity as detected by a clonogenic assay
To validate the hypothesis that the level of protein produced is too low to be detected by classical methods but sufficient to induce a cytotoxic activation, we used a functional cytotoxicity assay: a 2-week coculture (Mo/U-937) clonogenic assay in semi-solid medium (see Figure 4 for the experimental procedure). The cytotoxic efficacy was determined by counting the number of residual tumoral colonies at day 15 ( Figure 5 ). This assay integrates both cytolytic and cytostatic effects.
As negative controls, we followed the influence of ExGen 500 alone, or combined with a reporter gene (E. coli ␤-galactosidase) on the cytotoxic monocyte activation in comparison with non-activated monocytes ( Figure 6 ). The non-significant variations observed in these conditions show that neither ExGen 500 nor ␤-galactosidase/ExGen induce any cytotoxicity different from that observed among a non-activated monocyte population. All results obtained with controls were independent of the presence of GM-CSF in the culture medium. This basic cytotoxicity is called the intrinsic cytotoxicity. To compare experiments carried out with different samples of monocytes we determined the 100% level of cell viability to be that represented by the mean of these negative controls.
As a positive control we studied the cytotoxicity obtained by monocytes activated with rhIFN-␥ (100 U/ml), instead of using a transfection step. In this condition, we observed a cytotoxicity of 25% (19% with 20 ng/ml of GM-CSF) ( Figure 6 ).
To measure the intrinsic monocyte cytotoxicity, we performed a clonogenic assay with U-937 cells alone (with the presence or absence of GM-CSF) and obtained 119% (113% with GM-CSF) of residual colonies. These results show that, monocytes in coculture conditions are able to develop a weak intrinsic cytotoxicity independent of any activation ( Figure 6 ).
We also tested the antiproliferative effect 100 U/ml rhIFN-␥ on U-937 alone. After 2 weeks of culture we observed 85% of cell viability. This latter result was not influenced by GM-CSF presence or absence in culture medium (data not shown).
Without GM-CSF, the cytotoxicity observed for pLo1 (24%) and pL20 (22%) plasmids was not different to the one observed with rhIFN-␥ used as a positive control (25%). For other plasmids, the cytotoxicity is weak for pLo2 (less than 10%) and null for pL3I33. In the presence of GM-CSF, the two last plasmids have not significantly modified their cytotoxicity levels whereas pLo1, pL20 and pLo2 have developed a more significant cytotoxicity than the positive control (rhIFN-␥), respectively, of 44%, 34% and 30% ( Figure 6 ). In this condition the cytotoxicity observed with pLo1 and pL20 is statistically significant in comparison to the one observed with the positive control (rhIFN-␥) (respectively P Ͻ 0.01 and P = 0.02; t test).
Discussion
The goal of this study was to obtain a tumoricidal activation of human monocytes (Mo) by transferring the IFN-␥ cDNA with a synthetic vector. We used peripheral blood monocytes instead of MdM to limit the ex vivo culture period, as MdM require 7 days of ex vivo culture. Human monocytes and MdM are difficult cells to transfect. Retrovirus vectors do not efficiently mediate gene transfer into these cells due to their quiescent state. Replication-defective adenovirus vectors were found to be efficient only for mature MdM. 28 Physical techniques such as electroporation or gene gun are efficient but lead to extensive cellular mortality. They cannot be used for adoptive immunotherapy protocols in which the ratio of effector cells over target cells is of prime concern. We therefore decided to test the potential efficiency of synthetic vectors on fresh human monocytes. As stated in the Introduction, we had earlier used a polycationic lipid (DOGS) to transfect monocytes with the ␤-galactosidase gene. A good transfection ratio and limited cell death (less than 10% after a 7-day culture period) 23 was observed. Unfortunately, important inter-individual variations in transfection efficiency were later seen. However, in all cases, the ␤-galactosidase mRNA was detected by RT-PCR. Electron microscopy studies showed numerous intra-cytoplasmic DNA/lipid particles in more than 90% of monocytes. A closer examination showed most of them to be in a population of large phagocytic vacuoles. 24 This apparent discrepancy may be explained by the fact that although DOGS has an important endosomal buffering capacity, most of the internalized DNA/lipid complexes are degraded in phagocytic vacuoles. This means that only minute quantities of protein are produced, and these are undetectable by classical histochemistry techniques. Although such levels are too low to correct a genetic disease, we thought they might be sufficient to induce autocrine cytotoxic activation of monocytes following transfer of the IFN-␥ cDNA.
We studied ExGen 500/IFN-␥ transfection efficiency by RT-PCR. IFN-␥ mRNA was found up to 2 weeks after transfection for all plasmids used. These results suggest that although non-lymphocytic cells do not normally express IFN-␥ mRNA, the transcriptional machinery required to produce IFN-␥ mRNA remains intact in culture. These data are in agreement with Ahuja et al 29 
who transduced CD34
+ hemopoietic progenitor retrovirally with IFN-␥ cDNA and then allowed them to differentiate into monocytes. Other authors have recently demonstrated (eg Ramesh et al 30 ) that the CMV IE promoter/ enhancer elements are able to induce much greater mRNA expression than other promoters in monocytic cell lines. These authors suggest that transcriptional regulation of CMV elements may be provided by macrophage-specific cell factors. We too used a CMV promoter, however unfortunately, we did not detect any IFN-␥ protein expression in the cell culture supernatant either in cell pellets, or by ELISA (sensitivity: 3 pg/ml) nor by Western blot. Likewise, we did not detect ␤-galactosidase expression by histochemical staining in transfection experiments carried out with pLo1, pLo2 and pCMV␤gal.
In contrast, clonogenic assays gave three kinds of responses with the four transgenes including the IFN-␥ cDNA. First, the cytotoxicity level obtained with pL3I33 is comparable to those obtained in negative controls. Monocytes transfected with this plasmid retain the basal cytotoxicity but are not capable of developing an additional cytotoxicity activity. Second, with pLo1 and pLo20, cytotoxicity levels at day 15 are at least equivalent to those obtained with rhIFN-␥ and are increased in the presence of GM-CSF. The third type of response is shown by the transfections realised with pLo2. This plasmid shows a weak cytotoxicity without GM-CSF, but in the presence of GM-CSF we obtained cytotoxicity levels similar to those observed with pL20 and pLo1. These differences in tumoricidal effects could have several origins.
The cytotoxicity induced with pLo1 and pL20 is probably of multifactorial origin. Both plasmids have a leader peptide sequence which is a structure necessary for protein secretion. One possibility is that cytotoxic activation results from an autocrine and/or paracrine mechanism, activating more monocytes as a consequence. This hypothesis is reinforced by the fact that pLo2, which does not contain the leader peptide, induces a very weak cytotoxicity (approximately 10% without GM-CSF). The potential secretion of IFN-␥ by the transfected cells could also act on the U-937 proliferation. It has been demonstrated that U-937 cells express IFN-␥ receptors 31 in a constitutive manner and that IFN-␥ induces an antiproliferative effect on this cell line. 32 In our clonogenic assay
Figure 5 Two weeks coculture clonogenic assay (human monocytes and U-937 cells). The cytotoxicity is determined by the percentage of residual U-937 colonies after 2 weeks of culture in semi-solid media. The results summarize three independent experiments; each one is shown in duplicate. The normalized 100% survival is determined by the mean of negative controls and includes the intrinsic cytotoxicity of the monocytes.

Figure 6 Residual colonies of U-937 after 2 weeks of coculture with monocytes. Toluidine blue staining of residual colonies of U-937 after 2 weeks of coculture with monocytes. The cocultures were carried out with non-activated monocytes (a), monocytes transfected with pCMV␤gal (b), monocytes transfected with pLo2 (c) or pLo1 (d). All experiments are carried out without GM-CSF.
conditions, we obtained a U-937 cells viability of 85% with rhIFN-␥ ( Figure 6 ). The absence of cytotoxicity when using pl3I33 may be explained by the presence of IFN-␥ poly-A in the plasmid. The 3Ј untranslated region (UTR) of most cytokine mRNAs including IFN-␥ contains adenosine-uridine (AU)-rich elements (AREs) that target the mRNAs for rapid degradation 33 and inhibit translation. 34 The 3Ј UTR of IFN-␥ contains five AREs. It has been demonstrated 35 that replacement of wild-type AREs by mutated forms (AUGAUA instead of AUUUA for example) is able to induce in vivo an expression level at least 100-fold larger. In our case, the association of very short half-life of mRNA and a weak transfection efficiency is probably responsible for a too low protein level to induce cellular activation (the other IFN-␥ cDNA plasmids have been constructed with BGH-polyA that do not contain AREs).
Remarkably, transfection of pLo1, pLo2 and pL20 plasmids in the presence of GM-CSF leads to a greater cytotoxicity than with rhIFN-␥. In our experimental conditions, it was not possible to determine precisely the impact of GM-CSF on the different cell populations. This cytokine is known to increase the ex vivo survival of human monocytes 36 by mechanisms not fully understood, but probably involving inhibition of Fas-Fas ligand-induced apoptosis 37 in the presence of GM-CSF. Kitagawa et al 38 have shown GM-CSF-induced intracellular alkalinization in monocytes. This phenomenon could contribute to minimizing the degradation of the complex (ExGen/plasmid) at acidic pH. While several studies have shown GM-CSF to be able to prime monocytes by enhancing the release of superoxide, 38 or by stimulating accessory cell function (transcriptional regulation of HLA-DR and IL-1 expression), 39 the role of GM-CSF in enhancing cytotoxicity is still controversial. 40, 41 Furthermore, it is still not clear whether GM-CSF activation of monocytes requires a second signal as proposed by Cannistra et al 42 and Hart et al 43 or discussed for IFN-␥. 44 Several groups have shown that combined treatment with GM-CSF and IFN-␥ led to a synergistic tumoricidal activity. 36, 45 In our clonogenic assays, GM-CSF does not increase cytotoxicity with non-activated monocytes, monocytes treated by ExGen 500 alone or transfected by pCMV␤gal, or with monocytes activated with rhIFN-␥. These results seem to indicate that GM-CSF alone is not able to activate the tumoricidal function of monocytes and that the activation pathway implicating rhIFN-␥ followed by GM-CSF is not synergistic at the level of cytotoxicity. As to the increase of cytotoxicity obtained with pLo1, pL20 and pLo2 in the presence of GM-CSF, we suggest that at the beginning of coculture (24 h after transfection), the intracellular levels of IFN-␥ are still not sufficient to activate monocytes. In this case the presence of GM-CSF is probably the first priming signal. After several days of coculture, the level of cytokine produced could rise above threshold levels and act synergistically on cytotoxicity as previously described. This hypothesis is reinforced by the fact that although GM-CSF is a very short-lived cytokine, some of the induced priming effects persisted from several days to weeks. 45 However, other authors have established that GM-CSF acts on U-937 cells by increasing cell maturation and limiting the proliferation phase.
32 GM-CSF is also able to induce IFN-␥ receptor expression 46 ,47 on U-937 and monocytes, so that the two cell types might become more sensitive to IFN-␥.
We have used a large effector:target cell ratio (E:T, 1000:1) in comparison to those described by other authors (up to 10:1). 36 In such studies, the cytotoxicity was mainly determined by chromium release, thus it is difficult to transpose or compare the results of these studies and our own. Still, it has been demonstrated that in antibodyindependent cytotoxicity models using monocytes, the degree of cytotoxicity was not a function of the E:T ratio, suggesting that target cell recognition, rather than effector cell potency, might be the limiting factor in determining cytotoxicity. 48 In conclusion, we have demonstrated that one can induce a tumoricidal activation of human monocytes by transferring IFN-␥ cDNA into this population with a chemical vector. We also show that despite low levels of transgene expression, the production of cytokine may be sufficient to obtain intracellular activation with cytotoxic effects. These data need to be tested and optimized on other tumor cell lines and animal models. Although this model needs be improved for clinical use, it suggests that the method has potential in the adoptive immunotherapy area.
Materials and methods
Plasmid construction (Figure 2 ) For all constructions, we used pcDNA3 plasmid (Promega, Madison, WI, USA) as a backbone so all cDNA IFN-␥ were under CMV promoter control. pL20: An elutriation fraction of lymphocytes was activated in RPMI complete medium (composition in culture cells) by PHA-P or PHA-L (Sigma, St Louis, MO, USA) at 5 g/ml for 10 6 cells/ml in the presence of 50 m ␤-mercaptoethanol (Sigma). Lymphocytes were harvested after 2, 3, 5 and 7 days culture. A Western blot was undertaken to follow IFN-␥ protein expression. The primary antibody used was a polyclonal rabbit anti-human IFN-␥ (Innogenetics, Ghent, Belgium) and the second one was peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (Dako, Glostrup, Denmark). The substrate used for revelation was 3,3Ј diaminobenzidine (DAB) (Sigma). rhIFN-␥ (Schering Plough, Kenilworth, NJ, USA) was used as a positive control. The IFN-␥ presence was observed at days 3, 5 and 7. We achieved total RNA extraction on days 2 and 3, with TriReagent (Euromedex, Strasbourg, France) and a reverse transcription with hexamer protocol. We undertook a polymerase chain reaction (PCR) of ␤-globin gene as control mRNA integrity, potential DNA contamination and quality of reverse transcription (RT) reaction. We obtained a 598 bp fragment by PCR using primers 5Ј CGG GAT CCT TTG GAC CTG ATC AGC TT 3Ј (forward/BamHI site) and 5Ј CCG GAA TTC AAA TTC AAA TAT TGC AGG CA 3Ј (reverse/EcoRI site), which contains leader peptide upstream of cDNA IFN-␥ and we cloned it into BamHI/EcoRI sites in pcDNA3 polylinker in order to generate pL20.
pLo1: We cloned the ␤-galactosidase gene (as described for pLo2 construction) in pL20.
pL3I33: IFN-␥ cDNA with constitutive polyA and without leader peptide comes from cDNA bank and was cloned by Transgene (Strasbourg, France) in an expression vector pTG13. This cDNA was subcloned in pcDNA3 to give pL3I33.
All plasmids were sequenced with T7 Sequencing Kit (Pharmacia, Uppsala, Sweden) using T7 and SP6 primers. Sequences obtained for pLo2 were compared with human IFN-␥ sequence supplied by R&D Systems. Three other plasmids pLo1, pL20 and pLl3I33 sequences were compared with the nucleotide sequence of human IFN-␥ cDNA described by Devos et al. 49 To validate our constructions, we tested IFN-␥ protein expression after NIH3T3 transfection by Western blot. Plasmids were propagated using standard procedures and purified by Nucleobond AX column chromatography (MachereyNagel, Dü ren, Germany).
Endotoxin levels LPS levels were determined with QCL-1000 chromogenic Limulus assay (Boerhinger Ingelheim, Verviers, Belgium). In batch 4L3360 used for our determinations, 2 ng of endotoxin gave 23 endotoxin units (EU). LPS content was expected by EU per plasmid micrograms: pLo1 0.02 EU/g, pLo2 3 EU/g, pL3I33 12 EU/g, pL20 0.1 EU/g and pCVM␤gal 3.5 EU/g.
Cells
Mononuclear cells: Human blood monocytes (Mo) were obtained from informed healthy blood donors by leukapheresis and then purified by counter flow elutriation as previously described 31 (purity Ͼ96%). Mo were counted in a Malassez chamber (Bioblock, Strasbourg, France) and live cell percentage was obtained by the trypan blue dye exclusion method. The cytological analysis was determined by May-Grü nwald-Giemsa staining. The fresh isolated Mo suspension was centrifuged and resuspended at 10 6 cells/ml in RPMI complete medium (RPMI 1640 culture medium supplemented with penicillin (100 U/ml), streptomycin sulfate (100 mg/ml), glutamine (2 mm) and 10% v/v heat denatured fetal calf serum (FCS)). Cells were seeded at 10 6 cells/ml in six-well culture plates (Falcon, Lincoln Park, NJ, USA).
Tumoral cell lines:
Human histiomonocytic cell line U-937 and LoVo (human colon carcinoma cells) were routinely grown, respectively in RPMI complete medium or in F12 medium supplemented the same as RPMI medium.
All culture reagents were purchased from Gibco Life Technologies (Grand Island, NY, USA).
Transfection procedure
Transfection of monocytes: After 18 h of incubation, cells were transfected with five plasmids using ExGen 500 cationic polymer (Euromedex). Four were constructions described previously and one was pCMV␤gal, as control. Two micrograms of plasmids were used for 10 6 cells and all the transfections were carried out in the presence of FCS. Three other controls were undertaken in this experiment.
In the first, we tested the ExGen 500 impact on Mo by transfection procedure without plasmids. The second, rhIFN-␥, was added at a final concentration of 100 U/ml as control for Mo activation. In the last control, Mo were kept in culture without any treatment until clonogenic assay.
Transfection of LoVo: The transfection procedure was the same as described for transfection monocytes (2 g of plasmids/10 6 cells). To test IFN-␥ impact on CMV promoter we have transfected LoVo cells with pCMV␤gal in the presence or absence of 100 U/ml of rhIFN-␥. Seventytwo h after transfection, ␤-galactosidase expression was measured using the Luminescent ␤-Galactosidase Detection Kit II (Clontech). Briefly, cells were lysed and the lysate was incubated with reaction buffer, which contains the Galacton-Star substrate (Clontech, Palo Alto, CA, USA). Cleavage of a galactoside moiety from this substrate by ␤-galactosidase yields a dioxenate anion, which further degrades with the concurrent production of light. Detection was performed in a scintillation counter and the results were given by c.p.m. for 1 mg of cellular protein (bicinchoninic acid (BCA), Pierce, Interchim, Montlucon, France).
IFN-␥ RT-PCR:
The mRNA extraction was realised on 10 6 cells transfected in the same conditions as described previously. We have followed mRNA levels at days 1, 7 and 14 after transfection. Total mRNA extraction was achieved with TriReagent. In view of plasmid DNA elimination, digestion by 1 unit of DNase RNase-free (Promega) over 45 min at 37°C was performed. The reverse transcription was performed with hexamer random primers protocol and mRNA integrity was controlled by a polymerase chain reaction (PCR) on ␤-globin mRNA. We used three specific couples of primers for each sort of cloned IFN-␥ cDNA. To detect mRNA from pLo1 and pL20, we used 5Ј TTT TCA GCT CTG CAT CGT TTT 3Ј (sense, position 118) and 5Ј CTC TTT TGG ATG CTC TGG TCA 3Ј (antisense, position 367) which gave a 249 bp fragment. The 5Ј CTG GAA AGA AGA ATC GGA CCG TAA 3Ј (sense, position 118) and 5Ј TTG GAA CAG CAT TTG GGA ACG T 3Ј (antisense, position 423) were used to amplify a 305 bp fragment in pLo2 transfection. At the end, a 423 bp fragment was obtained by using 5Ј GCT AAA ACA GGG AAG CGA AAA AGG 3Ј (sense, position 529) and 5Ј CAG TAA CTG GAT AGT ATC ACT TCA C 3Ј (antisense, position 952) on pL3I33 transfection. The position of the primers is given according to the published sequence 49 for pLo1, pL20, pL3I33. For pLo2, the positions are determined according to the sequence manufacturer.
Clonogenic assays (plasma clot): In this test, Mo cytotoxicity was determined by their capacity to kill target cells (U-937 cell line) in a semi-solid medium. This medium was obtained by recalcification of bovine plasma citrated (PBC) (Gibco) at 10% v/v by using RPMI complete medium with 64 g/ml of CaCl 2 . Mo starved overnight after transfection, were harvested separately for each condition. Two milliliters of cold dextran solution was placed into wells and incubated on ice for 15 min. This solution was pooled with the first harvest cells in medium. Mo were washed twice in phosphate buffered saline. Live cells were counted by the trypan blue dye exclusion method and their final concentrations were adjusted at 10 6 cells/ml. The follow manipulation was the same for the height conditions (pLo1, pLo2, pL20, pL3I33, pCMV␤, ExGen 500 control, rhIFN-␥ control, Mo alone), U-937 alone and U-937 with rhIFN-␥. Assays without GM-CSF: 4 ml were prepared with 1 × 10 5 Mo/ml, 100 U-937/ml, 10% PBC and with RPMI complete medium at 64 g/ml CaCl 2 . Twice 1.5 ml were distributed. For the assays with rhINF-␥ (rhIFN-␥ positive control and U-937 with rhIFN-␥), we added 100 U/ml. In the series of assays with GM-CSF, the preparations were the same as previously described except for the addition of 20 ng/ml of GM-CSF. All dishes were placed in a CO 2 incubator for 14 days at 37°C.
After 2 weeks culture time, the U-937 forming colonies were stained by toluidine blue dye (0.05% alcoholic solution) and counted under a stereoscopic binoscope (× 1.6). A colony was considered as a 50 cell group.
